US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

156.76

+2.731.77%

Post-market: 156.760.00000.00%19:30 EDT

Volume:878.44K

Turnover:137.13M

Market Cap:15.99B

PE:22.98

High:157.03

Open:154.31

Low:153.70

Close:154.03

52wk High:186.12

52wk Low:122.14

Shares:102.00M

Float Shares:100.00M

Volume Ratio:0.81

T/O Rate:0.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.82

EPS(LYR):4.67

ROE:22.09%

ROA:11.70%

PB:4.33

PE(LYR):33.57

Loading ...

Overview Company News Filings

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

THOMSON REUTERS

Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating Nbip-'2118, A Corticotropin-Releasing Factor Type 2 Receptor Agonist

Neurocrine initiates Phase 1 study of NBIP-‘2118

Neurocrine initiates Phase 1 trial of obesity drug candidate NBIP-2118

Neurocrine Biosciences Inc - Initial Data From Phase 1 Nbip-'2118 Study Expected in 2027

THOMSON REUTERS

Neurocrine presents two-year Crenessity data

Neurocrine says Phase 3 pediatric CAH trial shows durable hormone control at two years

Neurocrine Biosciences Presents New Two-Year Crenessity® (Crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients With Classic Congenital Adrenal Hyperplasia

THOMSON REUTERS

Earning Preview: Neurocrine Biosciences revenue expected to increase by 37.63%, institutions are bullish

A Look At Neurocrine Biosciences (NBIX) Valuation After CRENESSITY Phase 3 CAHtalyst Adult Results

Simply Wall St.

Needham Sticks to Its Buy Rating for Neurocrine (NBIX)

Transthera Sciences publishes 2025 annual report

Neurocrine says crinecerfont cuts CAH glucocorticoid dose 38% at two years

Neurocrine Is Maintained at Outperform by Leerink Partners

A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity

Simply Wall St.

Neurocrine Biosciences publishes 2025 annual report

Neurocrine Biosciences announces annual shareholder meeting

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) and Mesoblast (MESO)

Neurocrine schedules first-quarter results conference call and webcast

Neurocrine claims analysis shows Ingrezza persistence tops Austedo XR in tardive dyskinesia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/NBIX/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBIX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBIX\",,,,,undefined,":{"symbol":"NBIX","market":"US","secType":"STK","nameCN":"Neurocrine Biosciences","latestPrice":156.76,"timestamp":1788292800000,"preClose":154.03,"halted":0,"volume":878438,"hourTrading":{"tag":"盘后","latestPrice":156.76,"preClose":156.76,"latestTime":"19:30 EDT","volume":24175,"amount":3789667.84,"timestamp":1788305406058,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.017723820035058038,"floatShares":99995570,"shares":102000000,"eps":6.823004,"marketStatus":"Closed","change":2.73,"latestTime":"09-01 16:00:00 EDT","open":154.31,"high":157.03,"low":153.7001,"amount":137125594.86956,"amplitude":0.021619,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.823004,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788336000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":832824000000,"exchange":"NASDAQ","adjPreClose":154.03,"preHourTrading":{"tag":"盘前","latestPrice":155.8,"preClose":154.03,"latestTime":"09:29 EDT","volume":1121,"amount":173637.90034000002,"timestamp":1788269366082,"change":1.77,"changeRate":0.011491,"amplitude":0.016166},"postHourTrading":{"tag":"盘后","latestPrice":156.76,"preClose":156.76,"latestTime":"19:30 EDT","volume":24175,"amount":3789667.84,"timestamp":1788305406058,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.80658,"impliedVol":0.2832,"impliedVolPercentile":0.1706},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBIX\",,,,,undefined,":{"symbol":"NBIX","floatShares":99995570,"roa":"11.70%","roe":"22.09%","lyrEps":4.67,"volumeRatio":0.80658,"shares":102000000,"dividePrice":0,"high":157.03,"amplitude":0.021619,"preClose":154.03,"low":153.7001,"week52Low":122.1375,"pbRate":"4.33","psRate":"4.74","week52High":186.12,"institutionHeld":0.95,"latestPrice":156.76,"eps":6.823004,"divideRate":0,"volume":878438,"delay":0,"ttmEps":6.823004,"open":154.31,"prevYearClose":141.83,"prevWeekClose":154.06,"prevMonthClose":154.03,"prevQuarterClose":168.535,"fiveDayClose":153.37,"twentyDayClose":166.06,"sixtyDayClose":163.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBIX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-30","symbol":"NBIX","fiscalQuarterEnding":"2026/06","expectedEps":1.88,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785384000000,"reportTimeType":"post","actualEps":2.36},{"market":"US","date":"2026-05-05","symbol":"NBIX","fiscalQuarterEnding":"2026/03","expectedEps":1.28,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777953600000,"reportTimeType":"post","actualEps":1.41},{"market":"US","date":"2026-02-11","symbol":"NBIX","fiscalQuarterEnding":"2025/12","expectedEps":1.78,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1770786000000,"reportTimeType":"post","actualEps":1.43},{"market":"US","date":"2025-10-28","symbol":"NBIX","fiscalQuarterEnding":"2025/09","expectedEps":1.58,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1761624000000,"reportTimeType":"post","actualEps":2.04},{"market":"US","date":"2025-07-30","symbol":"NBIX","fiscalQuarterEnding":"2025/06","expectedEps":0.98,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"post","actualEps":1.06}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBIX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBIX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.4667,"hold":0.1333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4667,"analysts":30,"updateTime":1780459200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBIX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBIX","date":"2026-08-31","current":22.975217,"percent":0.063518,"low":15.452095,"twenty":27.727905,"median":40.453654,"eighty":110.387029,"high":905.986584,"avg":99.912487,"sd":176.093425,"marketCap":15660072824},"quantilePoints":[{"date":"2021-09-03","current":24.880046,"twenty":-57.788755,"median":21.578659,"eighty":264.839255,"marketCap":9073752956},{"date":"2021-09-10","current":25.105828,"twenty":-57.393419,"median":21.731847,"eighty":264.839255,"marketCap":9156095347},{"date":"2021-09-17","current":25.043543,"twenty":-57.122936,"median":21.874823,"eighty":264.839255,"marketCap":9133380205},{"date":"2021-09-24","current":24.65167,"twenty":-56.515676,"median":21.983228,"eighty":264.839255,"marketCap":8990464100},{"date":"2021-10-01","current":26.330755,"twenty":-56.073302,"median":22.061434,"eighty":264.839255,"marketCap":9602826483},{"date":"2021-10-08","current":27.010694,"twenty":-54.272284,"median":22.130844,"eighty":264.839255,"marketCap":9850800122},{"date":"2021-10-15","current":27.130073,"twenty":-53.483205,"median":22.199493,"eighty":264.839255,"marketCap":9894337478},{"date":"2021-10-22","current":26.870554,"twenty":-53.14751,"median":22.365311,"eighty":264.839255,"marketCap":9799691051},{"date":"2021-10-29","current":27.355854,"twenty":-53.059611,"median":22.416552,"eighty":264.839255,"marketCap":9976679870},{"date":"2021-11-05","current":19.879776,"twenty":-52.91578,"median":22.430689,"eighty":264.839255,"marketCap":8842524454},{"date":"2021-11-12","current":18.76859,"twenty":-52.59512,"median":22.430689,"eighty":264.839255,"marketCap":8348268984},{"date":"2021-11-19","current":18.346297,"twenty":-52.419753,"median":22.430689,"eighty":264.839255,"marketCap":8160432931},{"date":"2021-11-26","current":18.551045,"twenty":-52.090504,"median":22.430689,"eighty":264.839255,"marketCap":8251504957},{"date":"2021-12-03","current":16.994105,"twenty":-51.971325,"median":22.430689,"eighty":264.839255,"marketCap":7558978098},{"date":"2021-12-10","current":16.987707,"twenty":-51.971325,"median":22.430689,"eighty":264.839255,"marketCap":7556132097},{"date":"2021-12-17","current":18.476398,"twenty":-51.971325,"median":22.430689,"eighty":264.839255,"marketCap":8218301614},{"date":"2021-12-23","current":18.147947,"twenty":-51.971325,"median":22.430689,"eighty":264.839255,"marketCap":8072206907},{"date":"2021-12-31","current":18.16501,"twenty":-51.971325,"median":22.430689,"eighty":264.839255,"marketCap":8079796242},{"date":"2022-01-07","current":16.064207,"twenty":-51.955042,"median":22.42362,"eighty":264.609771,"marketCap":7145359316},{"date":"2022-01-14","current":16.712577,"twenty":-51.955042,"median":22.42362,"eighty":264.609771,"marketCap":7433754063},{"date":"2022-01-21","current":16.017286,"twenty":-51.955042,"median":22.42362,"eighty":264.609771,"marketCap":7124488644},{"date":"2022-01-28","current":16.364931,"twenty":-51.955042,"median":22.42362,"eighty":264.609771,"marketCap":7279121353},{"date":"2022-02-04","current":17.305493,"twenty":-51.955042,"median":22.42362,"eighty":264.609771,"marketCap":7697483470},{"date":"2022-02-11","current":90.557458,"twenty":-51.955042,"median":22.431842,"eighty":264.609771,"marketCap":8113948252},{"date":"2022-02-18","current":90.693144,"twenty":-51.955042,"median":22.522526,"eighty":264.609771,"marketCap":8126105713},{"date":"2022-02-25","current":94.45608,"twenty":-51.955042,"median":22.586516,"eighty":264.609771,"marketCap":8463264811},{"date":"2022-03-04","current":93.743886,"twenty":-51.955042,"median":22.661461,"eighty":264.609771,"marketCap":8399452213},{"date":"2022-03-11","current":94.91316,"twenty":-51.955042,"median":22.80063,"eighty":264.609771,"marketCap":8504219165},{"date":"2022-03-18","current":98.99499,"twenty":-51.908672,"median":22.903884,"eighty":264.609771,"marketCap":8869951067},{"date":"2022-03-25","current":99.622146,"twenty":-51.908672,"median":23.045631,"eighty":264.609771,"marketCap":8926144250},{"date":"2022-04-01","current":101.588652,"twenty":-51.908672,"median":23.1378,"eighty":264.609771,"marketCap":9102343214},{"date":"2022-04-08","current":106.372046,"twenty":-51.908672,"median":23.19199,"eighty":264.609771,"marketCap":9530935287},{"date":"2022-04-14","current":105.521665,"twenty":-51.879725,"median":23.286066,"eighty":264.609771,"marketCap":9454741141},{"date":"2022-04-22","current":99.794282,"twenty":-51.235376,"median":23.504791,"eighty":264.609771,"marketCap":8941567652},{"date":"2022-04-29","current":95.96752,"twenty":-50.869461,"median":23.733072,"eighty":264.609771,"marketCap":8598689764},{"date":"2022-05-06","current":106.411117,"twenty":-50.538701,"median":24.05378,"eighty":264.609771,"marketCap":7597753757},{"date":"2022-05-13","current":112.603765,"twenty":-50.513367,"median":24.270178,"eighty":264.609771,"marketCap":8039908807},{"date":"2022-05-20","current":115.361299,"twenty":-50.513367,"median":24.572517,"eighty":264.609771,"marketCap":8236796731},{"date":"2022-05-27","current":124.624471,"twenty":-50.513367,"median":24.659455,"eighty":264.609771,"marketCap":8898187232},{"date":"2022-06-03","current":127.890676,"twenty":-50.513367,"median":24.724335,"eighty":264.609771,"marketCap":9131394287},{"date":"2022-06-10","current":126.244188,"twenty":-50.513367,"median":24.885236,"eighty":264.609771,"marketCap":9013834993},{"date":"2022-06-17","current":124.865421,"twenty":-50.513367,"median":25.0449,"eighty":264.609771,"marketCap":8915391031},{"date":"2022-06-24","current":131.50492,"twenty":-50.518997,"median":25.258455,"eighty":264.839255,"marketCap":9389451274},{"date":"2022-07-01","current":132.856915,"twenty":-50.518997,"median":25.998572,"eighty":264.839255,"marketCap":9485983703},{"date":"2022-07-08","current":127.930835,"twenty":-50.518997,"median":26.276232,"eighty":264.839255,"marketCap":9134261587},{"date":"2022-07-15","current":127.395391,"twenty":-50.518997,"median":26.439753,"eighty":264.839255,"marketCap":9096030922},{"date":"2022-07-22","current":127.556024,"twenty":-50.518997,"median":26.634392,"eighty":264.839255,"marketCap":9107500121},{"date":"2022-07-29","current":126.003238,"twenty":-50.518997,"median":26.826436,"eighty":264.839255,"marketCap":8996631194},{"date":"2022-08-05","current":815.065239,"twenty":-50.518997,"median":26.995123,"eighty":267.473329,"marketCap":9943795914},{"date":"2022-08-12","current":828.064055,"twenty":-50.518997,"median":27.355854,"eighty":332.018448,"marketCap":10102381477},{"date":"2022-08-19","current":838.803881,"twenty":-50.518997,"median":43.704114,"eighty":339.430085,"marketCap":10233407347},{"date":"2022-08-26","current":822.106196,"twenty":-50.518997,"median":44.350706,"eighty":343.175456,"marketCap":10029695593},{"date":"2022-09-02","current":807.525119,"twenty":-50.518997,"median":44.8698,"eighty":348.23866,"marketCap":9851806456},{"date":"2022-09-09","current":834.962629,"twenty":-50.518997,"median":45.079259,"eighty":349.917301,"marketCap":10186544079},{"date":"2022-09-16","current":831.670128,"twenty":-50.518997,"median":45.502731,"eighty":362.813526,"marketCap":10146375564},{"date":"2022-09-23","current":811.366371,"twenty":-50.518997,"median":45.962631,"eighty":364.154541,"marketCap":9898669723},{"date":"2022-09-30","current":832.610843,"twenty":-50.518997,"median":46.285926,"eighty":365.308101,"marketCap":10157852283},{"date":"2022-10-07","current":848.602992,"twenty":-50.518997,"median":47.210279,"eighty":371.273896,"marketCap":10352956498},{"date":"2022-10-14","current":848.446206,"twenty":-50.518997,"median":49.327638,"eighty":378.797857,"marketCap":10351043711},{"date":"2022-10-21","current":869.690678,"twenty":-50.518997,"median":50.903135,"eighty":389.463975,"marketCap":10610226271},{"date":"2022-10-28","current":905.986584,"twenty":-50.518997,"median":51.513299,"eighty":431.928138,"marketCap":11053036327},{"date":"2022-11-04","current":201.221497,"twenty":-50.458475,"median":52.087035,"eighty":434.881702,"marketCap":11711091146},{"date":"2022-11-11","current":200.593816,"twenty":-50.126307,"median":52.792822,"eighty":434.881702,"marketCap":11674560078},{"date":"2022-11-18","current":198.47952,"twenty":-49.947556,"median":54.395533,"eighty":434.881702,"marketCap":11551508062},{"date":"2022-11-25","current":201.766589,"twenty":-49.629464,"median":57.560591,"eighty":434.881702,"marketCap":11742815494},{"date":"2022-12-02","current":209.463947,"twenty":-49.385812,"median":59.991394,"eighty":434.881702,"marketCap":12190801742},{"date":"2022-12-09","current":193.656283,"twenty":-48.929381,"median":62.264354,"eighty":434.881702,"marketCap":11270795649},{"date":"2022-12-16","current":193.573693,"twenty":-48.286719,"median":62.627396,"eighty":434.881702,"marketCap":11265988929},{"date":"2022-12-23","current":198.727289,"twenty":-40.846451,"median":63.253512,"eighty":434.881702,"marketCap":11565928220},{"date":"2022-12-30","current":197.290229,"twenty":-39.648276,"median":63.753352,"eighty":434.881702,"marketCap":11482291302},{"date":"2023-01-06","current":203.20365,"twenty":-39.648276,"median":64.910878,"eighty":434.881702,"marketCap":11826452411},{"date":"2023-01-13","current":180.028985,"twenty":-39.648276,"median":65.66327,"eighty":434.881702,"marketCap":10477686948},{"date":"2023-01-20","current":183.943736,"twenty":-39.648276,"median":66.031573,"eighty":434.881702,"marketCap":10705525447},{"date":"2023-01-27","current":178.806658,"twenty":-37.833689,"median":67.168053,"eighty":434.881702,"marketCap":10406547501},{"date":"2023-02-03","current":181.746851,"twenty":-35.951624,"median":67.783646,"eighty":434.881702,"marketCap":10577666711},{"date":"2023-02-10","current":64.510722,"twenty":15.966099,"median":67.783646,"eighty":434.881702,"marketCap":9966906536},{"date":"2023-02-17","current":64.729529,"twenty":16.188336,"median":67.783646,"eighty":434.881702,"marketCap":10000712304},{"date":"2023-02-24","current":64.0481,"twenty":16.573519,"median":67.783646,"eighty":434.881702,"marketCap":9895431481},{"date":"2023-03-03","current":63.254141,"twenty":16.938226,"median":67.783646,"eighty":434.881702,"marketCap":9772764834},{"date":"2023-03-10","current":59.897008,"twenty":17.137429,"median":67.783646,"eighty":434.881702,"marketCap":9254087752},{"date":"2023-03-17","current":58.921752,"twenty":17.302081,"median":67.783646,"eighty":434.881702,"marketCap":9103410611},{"date":"2023-03-24","current":60.672212,"twenty":17.624986,"median":67.783646,"eighty":434.881702,"marketCap":9373856762},{"date":"2023-03-31","current":63.279148,"twenty":17.970498,"median":67.68894,"eighty":434.086512,"marketCap":9776628351},{"date":"2023-04-06","current":63.898061,"twenty":18.054957,"median":67.68894,"eighty":434.086512,"marketCap":9872250383},{"date":"2023-04-14","current":64.873317,"twenty":18.158185,"median":67.783646,"eighty":434.881702,"marketCap":10022927524},{"date":"2023-04-21","current":65.367197,"twenty":18.484076,"median":67.783646,"eighty":434.881702,"marketCap":10099231974},{"date":"2023-04-28","current":63.70426,"twenty":18.731906,"median":67.783646,"eighty":434.881702,"marketCap":9842308130},{"date":"2023-05-05","current":146.11832,"twenty":19.078272,"median":68.588653,"eighty":434.881702,"marketCap":9351572473},{"date":"2023-05-12","current":149.137041,"twenty":19.909208,"median":69.22003,"eighty":434.881702,"marketCap":9544770653},{"date":"2023-05-19","current":144.639451,"twenty":20.507993,"median":87.443915,"eighty":434.881702,"marketCap":9256924881},{"date":"2023-05-26","current":140.538259,"twenty":21.155662,"median":90.238157,"eighty":434.881702,"marketCap":8994448566},{"date":"2023-06-02","current":139.028898,"twenty":21.398536,"median":90.937629,"eighty":434.881702,"marketCap":8897849477},{"date":"2023-06-09","current":143.358782,"twenty":21.506213,"median":91.668604,"eighty":434.881702,"marketCap":9174962017},{"date":"2023-06-16","current":147.658173,"twenty":21.60402,"median":92.617131,"eighty":434.881702,"marketCap":9450123060},{"date":"2023-06-23","current":149.18278,"twenty":21.770569,"median":93.488972,"eighty":435.676893,"marketCap":9547697898},{"date":"2023-06-30","current":144.060101,"twenty":21.895923,"median":94.02934,"eighty":436.472083,"marketCap":9219846442},{"date":"2023-07-07","current":143.922886,"twenty":21.989585,"median":94.91316,"eighty":436.472083,"marketCap":9211064707},{"date":"2023-07-14","current":146.407995,"twenty":22.061764,"median":95.529687,"eighty":436.472083,"marketCap":9370111693},{"date":"2023-07-21","current":149.274256,"twenty":22.130933,"median":95.839905,"eighty":436.472083,"marketCap":9553552388},{"date":"2023-07-28","current":154.366443,"twenty":22.209371,"median":96.635182,"eighty":436.472083,"marketCap":9879452347},{"date":"2023-08-04","current":57.179827,"twenty":22.369622,"median":96.794628,"eighty":436.472083,"marketCap":10086521560},{"date":"2023-08-11","current":57.938239,"twenty":22.419379,"median":96.794628,"eighty":436.472083,"marketCap":10220305417},{"date":"2023-08-18","current":57.738949,"twenty":22.500257,"median":96.794628,"eighty":436.472083,"marketCap":10185150535},{"date":"2023-08-25","current":59.27238,"twenty":22.577261,"median":96.794628,"eighty":436.472083,"marketCap":10455647821},{"date":"2023-09-01","current":60.279905,"twenty":22.655218,"median":96.794628,"eighty":436.472083,"marketCap":10633375280},{"date":"2023-09-08","current":60.052935,"twenty":22.776647,"median":96.794628,"eighty":436.472083,"marketCap":10593337776},{"date":"2023-09-15","current":62.986937,"twenty":22.862726,"median":96.982474,"eighty":437.267273,"marketCap":11110895761},{"date":"2023-09-22","current":62.616035,"twenty":22.973265,"median":96.982474,"eighty":437.267273,"marketCap":11045468619},{"date":"2023-09-29","current":63.750885,"twenty":23.123786,"median":96.982474,"eighty":437.267273,"marketCap":11245656142},{"date":"2023-10-06","current":63.828387,"twenty":23.187287,"median":96.982474,"eighty":437.267273,"marketCap":11259327485},{"date":"2023-10-13","current":61.580831,"twenty":23.281362,"median":96.982474,"eighty":437.267273,"marketCap":10862858538},{"date":"2023-10-20","current":61.519936,"twenty":23.429531,"median":96.982474,"eighty":437.267273,"marketCap":10852116768},{"date":"2023-10-27","current":59.742927,"twenty":23.646846,"median":97.20033,"eighty":438.237231,"marketCap":10538652404},{"date":"2023-11-03","current":58.32872,"twenty":23.985048,"median":97.20033,"eighty":438.237231,"marketCap":11140785548},{"date":"2023-11-10","current":57.690854,"twenty":23.985048,"median":95.96752,"eighty":392.709437,"marketCap":11018953164},{"date":"2023-11-17","current":55.952155,"twenty":23.985048,"median":95.589827,"eighty":383.351833,"marketCap":10686861664},{"date":"2023-11-24","current":57.701142,"twenty":23.985048,"median":95.489796,"eighty":377.211039,"marketCap":11020918202},{"date":"2023-12-01","current":59.974826,"twenty":23.985048,"median":94.859599,"eighty":367.477481,"marketCap":11455191702},{"date":"2023-12-08","current":61.728957,"twenty":24.007626,"median":93.696554,"eighty":365.084276,"marketCap":11790230760},{"date":"2023-12-15","current":62.423408,"twenty":24.007626,"median":93.180509,"eighty":363.965151,"marketCap":11922870856},{"date":"2023-12-22","current":62.32567,"twenty":24.007626,"median":91.967766,"eighty":361.900364,"marketCap":11904202990},{"date":"2023-12-29","current":67.979014,"twenty":23.985048,"median":91.60565,"eighty":350.289361,"marketCap":12983991624},{"date":"2024-01-05","current":68.714617,"twenty":23.96247,"median":91.018028,"eighty":348.300433,"marketCap":13124491874},{"date":"2024-01-12","current":67.171393,"twenty":23.96247,"median":90.125498,"eighty":344.013234,"marketCap":12829736105},{"date":"2024-01-19","current":70.34529,"twenty":23.939892,"median":87.443915,"eighty":339.611278,"marketCap":13435950470},{"date":"2024-01-26","current":72.536668,"twenty":23.96247,"median":71.993968,"eighty":332.715749,"marketCap":13854503662},{"date":"2024-02-02","current":73.277416,"twenty":23.96247,"median":71.906519,"eighty":313.773789,"marketCap":13995986431},{"date":"2024-02-09","current":52.891564,"twenty":23.96247,"median":70.886562,"eighty":261.06275,"marketCap":13207023489},{"date":"2024-02-16","current":53.400095,"twenty":23.96247,"median":69.696194,"eighty":257.160449,"marketCap":13334003660},{"date":"2024-02-23","current":53.149035,"twenty":23.96247,"median":68.840647,"eighty":255.027964,"marketCap":13271313941},{"date":"2024-03-01","current":51.965465,"twenty":23.985048,"median":68.588653,"eighty":248.779166,"marketCap":12975776696},{"date":"2024-03-08","current":53.930111,"twenty":23.985048,"median":68.148768,"eighty":244.412047,"marketCap":13466348621},{"date":"2024-03-15","current":55.456397,"twenty":23.985048,"median":67.762962,"eighty":240.453561,"marketCap":13847462308},{"date":"2024-03-22","current":57.281564,"twenty":23.985048,"median":67.173314,"eighty":238.312647,"marketCap":14303206612},{"date":"2024-03-28","current":54.926381,"twenty":23.985048,"median":66.336739,"eighty":235.829511,"marketCap":13715117346},{"date":"2024-04-05","current":54.838709,"twenty":23.96247,"median":65.960543,"eighty":230.641182,"marketCap":13693225698},{"date":"2024-04-12","current":54.753332,"twenty":23.96247,"median":65.52974,"eighty":224.225614,"marketCap":13671906957},{"date":"2024-04-19","current":53.387822,"twenty":23.96247,"median":65.224959,"eighty":214.926531,"marketCap":13330939072},{"date":"2024-04-26","current":55.490466,"twenty":23.985048,"median":65.016713,"eighty":211.299293,"marketCap":13855969266},{"date":"2024-05-03","current":38.063574,"twenty":24.176232,"median":64.926662,"eighty":209.711716,"marketCap":14072103451},{"date":"2024-05-10","current":38.017298,"twenty":24.502187,"median":64.926662,"eighty":209.711716,"marketCap":14054995122},{"date":"2024-05-17","current":38.629778,"twenty":24.632825,"median":64.926662,"eighty":209.711716,"marketCap":14281428883},{"date":"2024-05-24","current":38.248679,"twenty":24.716549,"median":64.926662,"eighty":209.711716,"marketCap":14140536765},{"date":"2024-05-31","current":37.200658,"twenty":24.820876,"median":64.926662,"eighty":209.711716,"marketCap":13753083441},{"date":"2024-06-07","current":36.223413,"twenty":24.997349,"median":64.926662,"eighty":209.711716,"marketCap":13391795796},{"date":"2024-06-14","current":37.091773,"twenty":25.132663,"median":64.971688,"eighty":209.794306,"marketCap":13712828551},{"date":"2024-06-21","current":36.495626,"twenty":25.611349,"median":65.016713,"eighty":209.876896,"marketCap":13492433023},{"date":"2024-06-28","current":36.560957,"twenty":26.148895,"median":65.029383,"eighty":211.299293,"marketCap":13516585958},{"date":"2024-07-05","current":37.628033,"twenty":26.322584,"median":65.029383,"eighty":211.299293,"marketCap":13911083888},{"date":"2024-07-12","current":39.879237,"twenty":26.601174,"median":65.029383,"eighty":211.299293,"marketCap":14743353755},{"date":"2024-07-15","current":40.131034,"twenty":26.615894,"median":65.029383,"eighty":211.299293,"marketCap":14836443190},{"date":"2024-08-02","current":45.591134,"twenty":26.86173,"median":65.123383,"eighty":209.546537,"marketCap":15464512534},{"date":"2024-08-09","current":43.679968,"twenty":26.86173,"median":64.926662,"eighty":203.758652,"marketCap":14816245015},{"date":"2024-08-16","current":43.989565,"twenty":26.86173,"median":64.824841,"eighty":201.969234,"marketCap":14921260314},{"date":"2024-08-23","current":45.418474,"twenty":26.86173,"median":64.529477,"eighty":201.100989,"marketCap":15405946309},{"date":"2024-08-30","current":38.232251,"twenty":26.86173,"median":64.341928,"eighty":199.724972,"marketCap":12968379659},{"date":"2024-09-06","current":36.082934,"twenty":26.86173,"median":64.216895,"eighty":198.7372,"marketCap":12239331141},{"date":"2024-09-13","current":36.103772,"twenty":26.86173,"median":63.998087,"eighty":198.373805,"marketCap":12246399478},{"date":"2024-09-20","current":35.859667,"twenty":26.86173,"median":63.828387,"eighty":196.979242,"marketCap":12163598954},{"date":"2024-09-27","current":34.511134,"twenty":26.86173,"median":63.679253,"eighty":196.20378,"marketCap":11706176546},{"date":"2024-10-04","current":33.305492,"twenty":26.86173,"median":63.327173,"eighty":193.88423,"marketCap":11297222738},{"date":"2024-10-11","current":33.463267,"twenty":26.86173,"median":63.274802,"eighty":189.672156,"marketCap":11350740150},{"date":"2024-10-18","current":35.264288,"twenty":26.86173,"median":63.195636,"eighty":182.652034,"marketCap":11961646456},{"date":"2024-10-25","current":34.389081,"twenty":26.86173,"median":62.986937,"eighty":181.026669,"marketCap":11664776284},{"date":"2024-10-31","current":32.619923,"twenty":26.86173,"median":62.892828,"eighty":179.513625,"marketCap":12588028444},{"date":"2024-11-08","current":32.528095,"twenty":26.852907,"median":62.621935,"eighty":178.558889,"marketCap":12552592025},{"date":"2024-11-15","current":32.238181,"twenty":26.852907,"median":62.553735,"eighty":154.18349,"marketCap":12440714189},{"date":"2024-11-22","current":32.795708,"twenty":26.852907,"median":62.388604,"eighty":149.95728,"marketCap":12655863875},{"date":"2024-11-29","current":33.254848,"twenty":26.852907,"median":62.257511,"eighty":149.213272,"marketCap":12833045969},{"date":"2024-12-06","current":33.168268,"twenty":26.852907,"median":61.886863,"eighty":148.618675,"marketCap":12799634488},{"date":"2024-12-13","current":33.265343,"twenty":26.852907,"median":61.550384,"eighty":147.743551,"marketCap":12837095845},{"date":"2024-12-20","current":35.40887,"twenty":26.852907,"median":61.259752,"eighty":146.444586,"marketCap":13664283108},{"date":"2024-12-27","current":36.476699,"twenty":26.852907,"median":61.063228,"eighty":145.764611,"marketCap":14076358036},{"date":"2025-01-03","current":36.169731,"twenty":26.852907,"median":60.907571,"eighty":144.785813,"marketCap":13957899150},{"date":"2025-01-10","current":36.392742,"twenty":26.844083,"median":60.680648,"eighty":144.044855,"marketCap":14043959024},{"date":"2025-01-17","current":37.234935,"twenty":26.844083,"median":60.329767,"eighty":143.386225,"marketCap":14368961609},{"date":"2025-01-24","current":38.719925,"twenty":26.844083,"median":60.247462,"eighty":142.678807,"marketCap":14942019125},{"date":"2025-01-31","current":40.218033,"twenty":26.844083,"median":59.974826,"eighty":141.016986,"marketCap":15520138987},{"date":"2025-02-07","current":44.648909,"twenty":26.844083,"median":59.754628,"eighty":137.028614,"marketCap":15238672574},{"date":"2025-02-14","current":34.141082,"twenty":26.844083,"median":59.521493,"eighty":131.55311,"marketCap":11652351200},{"date":"2025-02-21","current":33.919064,"twenty":26.844083,"median":59.27238,"eighty":130.444741,"marketCap":11576576519},{"date":"2025-02-28","current":34.328044,"twenty":26.844083,"median":59.040533,"eighty":129.095424,"marketCap":11716161457},{"date":"2025-03-07","current":32.91122,"twenty":26.83526,"median":58.73161,"eighty":127.751461,"marketCap":11232599351},{"date":"2025-03-14","current":31.839108,"twenty":26.83526,"median":58.3673,"eighty":127.30972,"marketCap":10866687407},{"date":"2025-03-21","current":32.154607,"twenty":26.83526,"median":57.889136,"eighty":126.142453,"marketCap":10974367216},{"date":"2025-03-28","current":33.302672,"twenty":26.83526,"median":57.695998,"eighty":125.695358,"marketCap":11366202078},{"date":"2025-04-04","current":30.054201,"twenty":26.83526,"median":57.273606,"eighty":124.678015,"marketCap":10257498857},{"date":"2025-04-11","current":26.501916,"twenty":26.750137,"median":56.720224,"eighty":122.876248,"marketCap":9045103969},{"date":"2025-04-17","current":29.242083,"twenty":26.695569,"median":56.384258,"eighty":119.27935,"marketCap":9980323052},{"date":"2025-04-25","current":30.658387,"twenty":26.680493,"median":56.257145,"eighty":115.693273,"marketCap":10463707627},{"date":"2025-05-02","current":30.898993,"twenty":26.680493,"median":56.044889,"eighty":114.003704,"marketCap":10545826362},{"date":"2025-05-09","current":38.032908,"twenty":26.680493,"median":55.948895,"eighty":113.591967,"marketCap":11630463166},{"date":"2025-05-16","current":38.922888,"twenty":26.680493,"median":55.567979,"eighty":113.591967,"marketCap":11902619171},{"date":"2025-05-23","current":38.550714,"twenty":26.680493,"median":55.400605,"eighty":113.591967,"marketCap":11788808478},{"date":"2025-05-30","current":40.019991,"twenty":26.680493,"median":55.045675,"eighty":113.591967,"marketCap":12238113301},{"date":"2025-06-06","current":40.327439,"twenty":26.680493,"median":54.834724,"eighty":113.591967,"marketCap":12332130830},{"date":"2025-06-13","current":40.456891,"twenty":26.680493,"median":54.478076,"eighty":113.591967,"marketCap":12371717158},{"date":"2025-06-20","current":41.201238,"twenty":26.665418,"median":53.930111,"eighty":113.621107,"marketCap":12599338544},{"date":"2025-06-27","current":41.00706,"twenty":26.665418,"median":53.569084,"eighty":113.621107,"marketCap":12539959052},{"date":"2025-07-03","current":41.783771,"twenty":26.665418,"median":53.336333,"eighty":113.621107,"marketCap":12777477020},{"date":"2025-07-11","current":43.664056,"twenty":26.665418,"median":53.065577,"eighty":113.621107,"marketCap":13352468434},{"date":"2025-07-18","current":43.401917,"twenty":26.665418,"median":52.829249,"eighty":113.621107,"marketCap":13272306120},{"date":"2025-07-25","current":42.602552,"twenty":26.665418,"median":52.511422,"eighty":113.621107,"marketCap":13027860544},{"date":"2025-08-01","current":36.514628,"twenty":26.665418,"median":52.087035,"eighty":113.621107,"marketCap":12718045027},{"date":"2025-08-08","current":35.765712,"twenty":26.665418,"median":51.986859,"eighty":113.621107,"marketCap":12457197656},{"date":"2025-08-15","current":37.391686,"twenty":26.665418,"median":51.677224,"eighty":113.621107,"marketCap":13023524078},{"date":"2025-08-22","current":38.522178,"twenty":26.665418,"median":50.766532,"eighty":113.621107,"marketCap":13417274672},{"date":"2025-08-29","current":39.564396,"twenty":26.665418,"median":49.022556,"eighty":113.621107,"marketCap":13780278999},{"date":"2025-09-05","current":39.980144,"twenty":26.660526,"median":47.055461,"eighty":113.639848,"marketCap":13925084004},{"date":"2025-09-12","current":40.891372,"twenty":26.665418,"median":46.381549,"eighty":113.621107,"marketCap":14242464836},{"date":"2025-09-19","current":41.477975,"twenty":26.665418,"median":46.003612,"eighty":113.621107,"marketCap":14446778746},{"date":"2025-09-26","current":40.119675,"twenty":26.665418,"median":46.003612,"eighty":113.621107,"marketCap":13973682943},{"date":"2025-10-03","current":38.937926,"twenty":26.665418,"median":46.003612,"eighty":113.621107,"marketCap":13562079677},{"date":"2025-10-10","current":39.430559,"twenty":26.665418,"median":45.680316,"eighty":113.621107,"marketCap":13733663689},{"date":"2025-10-17","current":39.160038,"twenty":26.665418,"median":45.489919,"eighty":113.621107,"marketCap":13639441255},{"date":"2025-10-24","current":40.911305,"twenty":26.665418,"median":45.418474,"eighty":113.621107,"marketCap":14249407541},{"date":"2025-10-31","current":32.157417,"twenty":26.665418,"median":45.329167,"eighty":113.621107,"marketCap":13763374551},{"date":"2025-11-07","current":36.06178,"twenty":26.665418,"median":44.861795,"eighty":113.621107,"marketCap":15434442050},{"date":"2025-11-14","current":33.58428,"twenty":26.665418,"median":43.968726,"eighty":113.621107,"marketCap":14374071952},{"date":"2025-11-21","current":32.376397,"twenty":26.665418,"median":43.66806,"eighty":113.621107,"marketCap":13857097908},{"date":"2025-11-28","current":35.446773,"twenty":26.665418,"median":43.352509,"eighty":113.621107,"marketCap":15171219007},{"date":"2025-12-05","current":35.926665,"twenty":26.665418,"median":43.191558,"eighty":113.621107,"marketCap":15376612745},{"date":"2025-12-12","current":36.050133,"twenty":26.665418,"median":42.725532,"eighty":113.621107,"marketCap":15429456765},{"date":"2025-12-19","current":33.042655,"twenty":26.665418,"median":41.783771,"eighty":113.621107,"marketCap":14142256204},{"date":"2025-12-26","current":34.228407,"twenty":26.665418,"median":41.688697,"eighty":113.621107,"marketCap":14649758207},{"date":"2026-01-02","current":33.040325,"twenty":26.665418,"median":41.424542,"eighty":113.621107,"marketCap":14141259147},{"date":"2026-01-09","current":31.582013,"twenty":26.665418,"median":41.053684,"eighty":113.621107,"marketCap":13517101477},{"date":"2026-01-16","current":31.064848,"twenty":26.665418,"median":40.948324,"eighty":113.621107,"marketCap":13295754828},{"date":"2026-01-23","current":32.001336,"twenty":26.665418,"median":40.689904,"eighty":113.246297,"marketCap":13696571734},{"date":"2026-01-30","current":32.138781,"twenty":26.665418,"median":40.57987,"eighty":112.603765,"marketCap":13755398096},{"date":"2026-02-06","current":32.131792,"twenty":26.764151,"median":40.453654,"eighty":110.060408,"marketCap":13752406925},{"date":"2026-02-13","current":25.645156,"twenty":26.870554,"median":40.453654,"eighty":110.060408,"marketCap":12273771423},{"date":"2026-02-20","current":27.282254,"twenty":26.921566,"median":40.453654,"eighty":110.060408,"marketCap":13057286536},{"date":"2026-02-27","current":27.395493,"twenty":26.995123,"median":40.453654,"eighty":110.060408,"marketCap":13111482806},{"date":"2026-03-06","current":27.185791,"twenty":27.241002,"median":40.453654,"eighty":110.060408,"marketCap":13011119343},{"date":"2026-03-13","current":26.795744,"twenty":27.246604,"median":40.453654,"eighty":110.060408,"marketCap":12824443302},{"date":"2026-03-20","current":27.198373,"twenty":27.355854,"median":40.453654,"eighty":110.060408,"marketCap":13017141151},{"date":"2026-03-27","current":27.768763,"twenty":27.410172,"median":40.453654,"eighty":110.060408,"marketCap":13290129770},{"date":"2026-04-02","current":27.798121,"twenty":27.462597,"median":40.453654,"eighty":110.060408,"marketCap":13304180655},{"date":"2026-04-10","current":27.605195,"twenty":27.596807,"median":40.453654,"eighty":110.060408,"marketCap":13211846269},{"date":"2026-04-17","current":26.927857,"twenty":27.596807,"median":40.453654,"eighty":110.060408,"marketCap":12887672283},{"date":"2026-04-24","current":27.360571,"twenty":27.626165,"median":40.453654,"eighty":110.060408,"marketCap":13094769408},{"date":"2026-05-01","current":27.671606,"twenty":27.654794,"median":40.453654,"eighty":110.060408,"marketCap":13243630754},{"date":"2026-05-08","current":22.496668,"twenty":27.694724,"median":40.453654,"eighty":110.060408,"marketCap":15041271956},{"date":"2026-05-15","current":23.919346,"twenty":27.694724,"median":40.453654,"eighty":110.060408,"marketCap":15992474796},{"date":"2026-05-22","current":23.385466,"twenty":27.694724,"median":40.453654,"eighty":110.060408,"marketCap":15635522356},{"date":"2026-05-29","current":23.519312,"twenty":27.715019,"median":40.453654,"eighty":110.223718,"marketCap":15725011841},{"date":"2026-06-05","current":25.167574,"twenty":27.694724,"median":40.453654,"eighty":110.060408,"marketCap":16827039655},{"date":"2026-06-12","current":24.469769,"twenty":27.694724,"median":40.453654,"eighty":110.060408,"marketCap":16360487733},{"date":"2026-06-18","current":23.911827,"twenty":27.694724,"median":40.453654,"eighty":110.060408,"marketCap":15987447297},{"date":"2026-06-26","current":24.690841,"twenty":27.715019,"median":40.453654,"eighty":110.223718,"marketCap":16508296208},{"date":"2026-07-02","current":25.230737,"twenty":27.715019,"median":40.453654,"eighty":110.223718,"marketCap":16869270647},{"date":"2026-07-10","current":27.152706,"twenty":27.715019,"median":40.453654,"eighty":110.223718,"marketCap":18154299430},{"date":"2026-07-17","current":25.799207,"twenty":27.715019,"median":40.453654,"eighty":110.223718,"marketCap":17249349583},{"date":"2026-07-24","current":26.190218,"twenty":27.715019,"median":40.453654,"eighty":110.223718,"marketCap":17510779539},{"date":"2026-07-31","current":26.438018,"twenty":27.727905,"median":40.453654,"eighty":110.387029,"marketCap":18652021846},{"date":"2026-08-07","current":23.027033,"twenty":27.727905,"median":40.453654,"eighty":110.387029,"marketCap":16245572107},{"date":"2026-08-14","current":21.730304,"twenty":27.727905,"median":40.453654,"eighty":110.387029,"marketCap":15330729478},{"date":"2026-08-21","current":22.034315,"twenty":27.727905,"median":40.453654,"eighty":110.387029,"marketCap":15545209250},{"date":"2026-08-28","current":22.465117,"twenty":27.727905,"median":40.453654,"eighty":110.387029,"marketCap":15849140301},{"date":"2026-08-31","current":22.197127,"twenty":27.727905,"median":40.453654,"eighty":110.387029,"marketCap":15660072824}],"updateTime":1788312584020},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBIX\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2632953989","title":"Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953989?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:31","pubTimestamp":1777897871,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41H07I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0823416689.USD","NBIX","LU2324357040.USD","LU0154245756.USD","BK4139","LU0154245673.USD","LU2065170008.USD","LU2065171402.SGD","LU0109394709.USD","LU2065171311.SGD","LU0320765992.SGD","LU0889565916.HKD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632958376","title":"Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating Nbip-'2118, A Corticotropin-Releasing Factor Type 2 Receptor Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2632958376","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632958376?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:51","pubTimestamp":1777895493,"startTime":"0","endTime":"0","summary":"May 4 (Reuters) - Neurocrine Biosciences Inc ::*NEUROCRINE BIOSCIENCES ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY EVALUATING NBIP-'2118, A CORTICOTROPIN-RELEASING FACTOR TYPE 2 RECEPTOR AGONIST*NE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nRSD3W57R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2065171311.SGD","NBIX","LU0823416689.USD","LU2324357040.USD","LU2065171402.SGD","LU0154245673.USD","LU0154245756.USD","LU2065169927.USD","LU0320765992.SGD","LU0109394709.USD","LU2065170008.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632740930","title":"Neurocrine initiates Phase 1 study of NBIP-‘2118","url":"https://stock-news.laohu8.com/highlight/detail?id=2632740930","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632740930?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:40","pubTimestamp":1777894816,"startTime":"0","endTime":"0","summary":"Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-‘2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurocrine-initiates-phase-1-study-of-nbip-2118-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurocrine-initiates-phase-1-study-of-nbip-2118-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171402.SGD","LU2065169927.USD","NBIX","LU2065170008.USD","LU0320765992.SGD","LU0154245673.USD","LU2065171311.SGD","LU0889565916.HKD","BK4139","LU2324357040.USD","LU0823416689.USD","LU0154245756.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930140","title":"Neurocrine initiates Phase 1 trial of obesity drug candidate NBIP-2118","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930140","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930140?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:32","pubTimestamp":1777894341,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences initiated Phase 1 first-in-human trial for NBIP-'2118, investigational once-weekly injectable obesity drug designed to drive weight loss while preserving lean mass.Study will test safety and tolerability across single ascending doses versus placebo in healthy-weight adults plus participants who are overweight or obese.No clinical results have been presented; initial data expected in 2027.Program positions CRF2 agonism as potential standalone option or combination partner with incretin-based approaches, supporting broader obesity pipeline strategy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL14dbQ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","NBIX","LU0154245756.USD","LU0154245673.USD","LU2324357040.USD","LU2065169927.USD","LU0889565916.HKD","LU2065171311.SGD","LU2065171402.SGD","BK4139","LU0320765992.SGD","LU0823416689.USD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930944","title":"Neurocrine Biosciences Inc - Initial Data From Phase 1 Nbip-'2118 Study Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930944?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:30","pubTimestamp":1777894205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA7TJB47:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU2065171402.SGD","LU2324357040.USD","LU0823416689.USD","LU2065170008.USD","LU2065171311.SGD","NBIX","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0154245756.USD","LU2065169927.USD","LU0154245673.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647937","title":"Neurocrine presents two-year Crenessity data","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647937?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:11","pubTimestamp":1777666302,"startTime":"0","endTime":"0","summary":"Neurocrine (NBIX) Biosciences announced the presentation of new two-year data from the Phase 3 CAHtalyst Pediatric study demonstrating durable andr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurocrine-presents-two-year-crenessity-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurocrine-presents-two-year-crenessity-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2324357040.USD","LU2065171311.SGD","LU0109394709.USD","NBIX","LU0154245673.USD","LU0320765992.SGD","LU0823416689.USD","LU0154245756.USD","LU2065169927.USD","LU2065171402.SGD","LU0889565916.HKD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642706","title":"Neurocrine says Phase 3 pediatric CAH trial shows durable hormone control at two years","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642706","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642706?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:06","pubTimestamp":1777665993,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences presented new two-year Phase 3 CAHtalyst Pediatric data for CRENESSITY  at Pediatric Endocrine Society 2026 Annual Meeting.Results showed sustained hormone control in children and adolescents with classic congenital adrenal hyperplasia while supporting lower, more physiologic glucocorticoid use.Clinical readouts pointed to improvements in cardiometabolic risk markers, including weight-related measures and insulin resistance, in patients who entered study with those issues.Data also indicated improvement in select signs linked to excess androgens, supporting broader symptom control over time.Neurocrine flagged plans to present additional two-year endpoint data at upcoming medical meetings, with no new safety signals reported in follow-up.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL6HVX7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245673.USD","LU0154245756.USD","LU0823416689.USD","LU2065171311.SGD","NBIX","LU0889565916.HKD","LU2065170008.USD","LU0320765992.SGD","LU2324357040.USD","BK4139","LU2065171402.SGD","LU0109394709.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632790642","title":"Neurocrine Biosciences Presents New Two-Year Crenessity® (Crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients With Classic Congenital Adrenal Hyperplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2632790642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632790642?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:05","pubTimestamp":1777665900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nTUA7WGRPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0154245756.USD","LU0109394709.USD","LU2065169927.USD","LU0154245673.USD","LU0889565916.HKD","LU0823416689.USD","LU2065170008.USD","LU2065171402.SGD","BK4139","LU2324357040.USD","NBIX","LU0320765992.SGD","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142171120","title":"Earning Preview: Neurocrine Biosciences revenue expected to increase by 37.63%, institutions are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1142171120","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142171120?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:01","pubTimestamp":1777374098,"startTime":"0","endTime":"0","summary":"Abstract Neurocrine Biosciences will report its fiscal first-quarter 2026 results on May 5, 2026 Post Market; this preview synthesizes current-quarter revenue and EPS expectations, last quarter’s...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Neurocrine Biosciences revenue expected to increase by 37.63%, institutions are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630354122","title":"A Look At Neurocrine Biosciences (NBIX) Valuation After CRENESSITY Phase 3 CAHtalyst Adult Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2630354122","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630354122?lang=en_us&edition=fundamental","pubTime":"2026-04-27 11:11","pubTimestamp":1777259465,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences (NBIX) is back in focus after new two year Phase 3 CAHtalyst Adult data for CRENESSITY in classic congenital adrenal hyperplasia, highlighting sustained glucocorticoid reductions and a clean safety profile.\nSee our latest analysis for Neurocrine Biosciences.\nAt a share price of $127.68, Neurocrine Biosciences has seen a 1 year total shareholder return of 19.63%, while its year to date share price return of 9.19% points to fading short term momentum following recent...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/a-look-at-neurocrine-biosciences-nbix-valuation-after-crenes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/a-look-at-neurocrine-biosciences-nbix-valuation-after-crenes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0154245756.USD","LU0823416689.USD","LU2065170008.USD","BK4139","NBIX","LU2065171402.SGD","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","LU0154245673.USD","LU2065169927.USD","LU2065171311.SGD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630387037","title":"Needham Sticks to Its Buy Rating for Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2630387037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630387037?lang=en_us&edition=fundamental","pubTime":"2026-04-26 20:25","pubTimestamp":1777206312,"startTime":"0","endTime":"0","summary":"In a report released on April 24, Ami Fadia from Needham maintained a Buy rating on Neurocrine. The company’s shares closed last Friday at $127.68....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629725858","title":"Transthera Sciences publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629725858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629725858?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:33","pubTimestamp":1776954802,"startTime":"0","endTime":"0","summary":"Global expansion remained central, supported by a registrational Phase III multi-regional trial for Tinengotinib across U.S., EU, U.K., South Korea, Taiwan; enrollment expected to complete in 2026.Pipeline breadth increased, with six clinical-stage candidates spanning oncology, inflammatory, cardiometabolic diseases; Tinengotinib programs advanced in prostate cancer, breast cancer, liver cancer.Business development accelerated via November 2025 NLRP3 collaboration with Neurocrine Biosciences, carrying potential total value up to USD 881.5 million.Management outlook targeted China NDA approval in 2026 for Tinengotinib, with commercialization team buildout planned for 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Scienc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL1LmypC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0154245673.USD","BK4139","LU2065169927.USD","LU2065170008.USD","LU0154245756.USD","LU0823416689.USD","BK1161","LU2065171402.SGD","LU2065171311.SGD","LU0320765992.SGD","02617","LU2324357040.USD","NBIX","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629562020","title":"Neurocrine says crinecerfont cuts CAH glucocorticoid dose 38% at two years","url":"https://stock-news.laohu8.com/highlight/detail?id=2629562020","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629562020?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:13","pubTimestamp":1776888806,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences presented new two-year Phase 3 CAHtalyst Adult data on CRENESSITY  at American Association of Clinical Endocrinology 2026 Annual Meeting.Results showed patients sustained meaningful reductions in chronic glucocorticoid use while maintaining control of disease-related androgen levels.About 70% of treated adults reached physiologic-range glucocorticoid dosing at two years, supporting potential shift away from long-term supraphysiologic regimens.Safety profile remained favorable over two years, with more than 80% of participants staying on study.Neurocrine flagged additional two-year readouts for presentation at upcoming medical meetings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL72mjrD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245756.USD","NBIX","LU2065170008.USD","LU2324357040.USD","LU2065171311.SGD","LU2065169927.USD","LU0823416689.USD","LU2065171402.SGD","LU0109394709.USD","LU0889565916.HKD","LU0154245673.USD","BK4139","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629040489","title":"Neurocrine Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2629040489","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629040489?lang=en_us&edition=fundamental","pubTime":"2026-04-22 22:35","pubTimestamp":1776868500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 10:35 ET (14:35 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU0889565916.HKD","LU2065170008.USD","LU2324357040.USD","LU0154245673.USD","NBIX","LU0109394709.USD","LU2065169927.USD","LU2065171402.SGD","BK4139","LU0154245756.USD","LU0320765992.SGD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628767667","title":"A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2628767667","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628767667?lang=en_us&edition=fundamental","pubTime":"2026-04-19 20:06","pubTimestamp":1776600418,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences (NBIX) is back in focus after new real world data showed higher treatment persistence for INGREZZA versus AUSTEDO XR in tardive dyskinesia, alongside elevated options activity implying expectations for larger share moves.\nSee our latest analysis for Neurocrine Biosciences.\nThe INGREZZA persistence data and recent M&A call interest come as the share price sits at US$133.25, with a 1 month share price return of 4.36% but a year to date share price decline of 5.23%, while...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/a-look-at-neurocrine-biosciences-nbix-valuation-after-new-in-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/a-look-at-neurocrine-biosciences-nbix-valuation-after-new-in-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0823416689.USD","LU2065169927.USD","LU2065170008.USD","LU2324357040.USD","BK4139","LU0154245756.USD","NBIX","LU0154245673.USD","LU2065171311.SGD","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627584782","title":"Neurocrine Biosciences publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2627584782","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627584782?lang=en_us&edition=fundamental","pubTime":"2026-04-16 05:12","pubTimestamp":1776287564,"startTime":"0","endTime":"0","summary":"Neurocrine 2025 annual report highlighted continued growth focus for INGREZZA in tardive dyskinesia and Huntington’s disease chorea, alongside ramp-up of CRENESSITY following its December 2024 US launch for classic congenital adrenal hyperplasia.Management outlined plan to expand INGREZZA and CRENESSITY sales teams, targeting completion by end of first quarter 2026 to increase prescriber reach in community, institutional, endocrinology, and rare disease settings.Pipeline strategy emphasized late-stage psychiatry programs, with Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia expected in 2027.Report reiterated reliance on third-party manufacturing while scaling internal capabilities to support expanded modalities, including peptides, antibodies, conjugates, and gene therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL9kdrYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065171311.SGD","NBIX","LU0889565916.HKD","LU0154245673.USD","LU2324357040.USD","BK4139","LU0154245756.USD","LU0109394709.USD","LU2065169927.USD","LU0320765992.SGD","LU0823416689.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627832230","title":"Neurocrine Biosciences announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627832230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627832230?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:17","pubTimestamp":1776284225,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences schedules annual shareholder meeting for May 27, 2026 in San Diego.Shareholders will vote on election of three Class III director nominees: Kevin Gorman, Gary Lyons, Johanna Mercier.Ballot includes advisory vote on compensation paid to named executive officers.Meeting will consider amendment to 2025 Equity Incentive Plan to add 4,000,000 shares to share reserve.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3hxP4j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0154245673.USD","LU0154245756.USD","LU2065171311.SGD","LU2065171402.SGD","LU2065169927.USD","LU2065170008.USD","LU0889565916.HKD","BK4139","NBIX","LU2324357040.USD","LU0320765992.SGD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627235186","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) and Mesoblast (MESO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627235186","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627235186?lang=en_us&edition=fundamental","pubTime":"2026-04-15 23:00","pubTimestamp":1776265224,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-galmed-pharmaceuticals-glmd-neurocrine-nbix-and-mesoblast-meso-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-galmed-pharmaceuticals-glmd-neurocrine-nbix-and-mesoblast-meso-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0154245756.USD","LU2324357040.USD","NBIX","LU2065171402.SGD","LU2065170008.USD","GLMD","LU0109394709.USD","LABU","XBI","LU0128526141.USD","LU0889565916.HKD","LU0029874061.USD","XLV","BK4588","BK4137","LU0320765992.SGD","LU0154245673.USD","MESO","LU0823416689.USD","BK4581","HCSG","LU2065169927.USD","LU2065171311.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627218764","title":"Neurocrine schedules first-quarter results conference call and webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2627218764","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627218764?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:01","pubTimestamp":1776196892,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences schedules Q1 2026 results release for May 5, 2026 at 1:00 p.m. PT.Management will host Q1 2026 earnings conference call plus webcast on May 5, 2026 at 1:30 p.m. PT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLbkHgrn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245756.USD","NBIX","LU2065170008.USD","BK4139","LU0109394709.USD","LU0154245673.USD","LU2065171402.SGD","LU2065171311.SGD","LU0823416689.USD","LU2324357040.USD","LU0320765992.SGD","LU0889565916.HKD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627193446","title":"Neurocrine claims analysis shows Ingrezza persistence tops Austedo XR in tardive dyskinesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2627193446","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627193446?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:32","pubTimestamp":1776169965,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences disclosed results from a real-world head-to-head claims analysis, presented at Academy of Managed Care Pharmacy 2026 Annual Meeting, showing higher treatment persistence for Ingrezza versus Austedo XR in adults with tardive dyskinesia.Study findings indicated patients starting on Ingrezza were more likely to stay on initial therapy over six months, supporting positioning as a durable first-line option.Analysis also showed lower switching away from Ingrezza versus Austedo XR, suggesting a more stable treatment course in routine care.Neurocrine said persistence differences emerged early in treatment and held through six-month follow-up, a factor that can influence payer and formulary decisions for VMAT2 inhibitors.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL1rrZ59:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU0889565916.HKD","LU0109394709.USD","LU2065171402.SGD","LU0154245673.USD","LU2324357040.USD","LU2065170008.USD","LU0823416689.USD","BK4139","LU2065169927.USD","NBIX","LU0320765992.SGD","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":199,"code":"91000000","status":"200"}]}}